PLUVICTO® lutetium Lu 177 vipivotide tetraxetan 是一款靶向肿瘤细胞表面PSMA(前列腺特异性膜抗原),进而释放放射性镥177(Lutetium-177)杀死肿瘤细胞的RDC核药。 药物由诺华公司开发,2022年获FDA批准上市,用于治疗去势抵抗型前列腺癌(mCRPC)成人患者。 药物国内尚未上市,根据英文名我暂称它为镥鲁177肽(音译无出处...
镥( 177 Lu) vipivotide tetraxetan,以品牌名称Pluvicto出售,是一种放射性药物,用于治疗前列腺特异性膜抗原(PSMA) 阳性的转移性去势抵抗性前列腺癌(mCRPC)。镥 ( 177 Lu) vipivotide tetraxetan 是一种靶向放射性配体疗法。 镥(177 Lu)vipivotide tetraxetan 于 2022 年 3 月在美国获批用于医疗用途,并于 202...
学习下核药(Pluvicto) 核药由载体(小分子、多肽、大分子等)、连接子和载体组成,更换螯合的核素可发挥不同作用,比如鳌合Ga-68(γ辐射)可肿瘤诊断,鳌合Lu-177(β辐射)可肿瘤治疗。 Pluvicto(lutetium Lu 177 vipivotide tetraxetan)结构式如下: Vipivotide tetraxetan (PSMA-617)可以结合到PSMA上,PSMA在80%以...
Since FDA approval in March 2022, there ... Kunal Desai,Kerry Roe Schaffer,Katy Beckermann,... - Journal of Clinical Oncology 被引量: 0发表: 2024年 1utetium 1u 177 vipivotide tetraxetan first approva1 Lutetium Lu 177 vipivotide tetraxetan (PLUVICTOTM, formerly known as 177Lu-PSMA-617)...
The Lutetium-177 market exhibits diverse dynamics across various geographies, each shaped by unique regulatory landscapes, healthcare infrastructures, and market demands. In the United States, the strong healthcare system, significant R&D...
FDA approval was based on pivotal Phase III VISION trial, where patients with pre-treated PSMA-positive mCRPC who received Pluvicto plus standard of care had a statistically significant reduction in risk of death1; both alternate primary endpoints of overall survival and radiographic progression free...
FDA Approves Pluvicto (lutetium Lu 177 vipivotide tetraxetan) Targeted Radioligand Therapy for Treatment of Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer FDA also approved complementary diagnostic imaging agent, Locametz, after radiolabeling with gallium-68 f...
Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901). Presented at the European Society of Medical Oncology (ESMO) Congress. October 20-24, 2023. Madrid, Spain. Abstract LBA84 National...
Food and Drug Administration (FDA) approved radiotherapeutic, PluvictoTM (lutetium Lu 177 vipivotide tetraxetan) for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate...
Treatment with lutetium-PSMA is based on the ability of PSMA ligand that is labeled with the radioisotope 177-lutetium to bind specifically to PSMA-expressing prostate cancer cells to cause cellular damage. Recently, the efficacy of lutetium PSMA has been demonstrated in castrate-resistant metastatic...